The Relentless Pursuit of Better
We never give up. We strive to do more for cancer patients - through richer science, deeper insights, and stronger partnerships - providing better cancer care today, and fueling better cancer care tomorrow.
PATIENT INFORMATION HEREFoundation Medicine, a molecular insights company, is connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands.
Better Care Today
1
Genomic Testing
Comprehensive Genomic Profiling
Our portfolio of genomic tests is the leading platform for comprehensive genomic profiling. We analyze more than 300 genes across the four main classes of genomic alterations to help understand the genomic makeup of a patient's tumor.
2
Molecular Insights
Valuable Insights, Actionable Options
We help match each patient’s unique genomic profile to known targeted therapies, immunotherapies and clinical trials and offer decision support services, financial assistance, and technology solutions to help streamline patient care.
Patient Story
Dealing with cancer is not just dealing with the cancer. It’s treating the whole person.
Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test.
Better Care Tomorrow
3
More Than Numbers
Insights, Not Just Information
Our unique knowledgebase, FoundationCore®, is one of the world's largest cancer genomic databases, with more than 400,000 anonymized patient records, designed to help researchers and biopharma companies advance precision medicine, develop new therapies, and design better trials.
4
Supporting Drug Development
The Preferred Partner to BioPharma
We partner with drug developers throughout each stage of drug research and development,
from target discovery to commercial launch. Today, we are working with more than 50
biopharma partners to accelerate new biomarker-driven treatments.
Advancing Cancer Care
The Power Of Partnership In Precision Medicine
FoundationOne CDx was recently approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel. Learn more on our blog about how this approval demonstrates the power of cancer precision medicine in action and the role that comprehensive genomic profiling plays.
Garrett Frampton, PhD, Sr. Director, Cancer Genomics
Better Care Together
5
Collective Advances
The Power of Collaboration
By sharing our genomic data, we empower researchers on the front lines to generate new connections and insights. Today, we proudly participate in a number of sharing initiatives to accelerate research efforts.
6
Transforming Cancer Care
Cultivating an Ecosystem of Partners
Every insight we gain towards better cancer care is multiplied by a hyper-connected network of physicians, biopharma, researchers, patient advocacy organizations and world-leading medical centers. Together, we are transforming cancer care.
We are deeply committed to the health and care of patients, and we acknowledge the extraordinary impact COVID-19 continues to have on patients with cancer, and the community at large. We have taken steps to keep our labs open and operational to continue to provide access to our portfolio of tests and services.
Join Us in the Pursuit of Better
Find out more about genomic testing, learn more about us, or read the latest updates from our blog.